Hello, Welcome to Shine Consultant !
Summit & Event Advisor & Insight Research & Analysis
Conference Sponsor
13
2019 - 09 - 24
点击次数:
Ph.D. from Dalhousie University, Canada, postdoctoral fellow in Harvard Medical School in the USA. Dr. Fang is a veteran drug researcher and entrepreneur. He is the founder, CEO and CSO of RemeGen. He is also the founder of MabPlex International. Dr. Fang is a professor at Tongji University in Shanghai and has more than 40 invention patents related to therapeutic development. He is the inventor of conbercept, an innovative biologics approved in China for ophthalmology indications.
14
2019 - 09 - 24
点击次数:
Dr. Jim Li is chief executive officer of Sundia. In this role, Dr. Li is responsible for the oversight of all business divisions across the organization as well as formulating and driving key strategies for diversifying and growing the company. Dr. Li also leads the company’s executive committee, helping to drive Sundia’s overall global strategy.Dr. Li has led a distinguished career in the pharmaceutical industry, having spent over 18 years at various companies including Henkel, Wyeth, Pfizer and Wuxi Apptec in the area of process research and medicinal chemistry. During his career, he was involved in numerous drug discovery programs such as COPD, asthma, Rheumatoid/osteoarthritis, and diabetes. Dr. Li has co-authored more than 60 research articles and patents.Dr. Li received his Ph.D in Organic Chemistry from University of Central Lancashire UK followed by a postdoctoral fellow at the University of Chicago with Dr. Philip Eaton.
15
2019 - 09 - 24
点击次数:
Dr. Giedrius Kalesnykas is Founder and Chief Executive Officer of Experimentica Ltd., a preclinical contract research organization specialized in ophthalmic models. He earned his Ph.D. in Neuroscience in 2005 from the University of Kuopio, Finland, and completed several postdoctoral fellowships studying the pathophysiology of glaucoma and ocular gene therapy. In 2009, Dr. Kalesnykas was awarded the prestigious position of Finnish Academy Research Fellow, which he held until 2013. He was a visiting researcher at the Wilmer Eye Institute at The Johns Hopkins University from 2010-2011. In 2013, he founded Experimentica Ltd., which under his leadership has grown to become one of the leading preclinical CROs dedicated to drug discovery and development for ophthalmic disorders.